IDMC Recommends Corautus Genetics' Phase IIb GENASIS Trial to Proceed

An independent data monitoring committee (IDMC) has recommended the continuation of Corautus Genetics' GENASIS trial based on an interim safety analysis.

The Phase IIb Genetic Angiogenic Stimulation Investigational Study (GENASIS) was designed to evaluate the safety and efficacy of vascular endothelial growth factor-2 for the treatment of patients with severe angina.

The planned interim safety analysis was conducted after the first 54 patients were treated in the trial. The IDMC comprises independent physicians and a statistician and was established to monitor the safety data from the trial.